Generated by AI
Travere Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for people living with rare kidney, liver, and metabolic diseases. Its current commercial portfolio includes FILSPARI, a treatment for certain kidney disorders, along with legacy rare-disease products such as Thiola, Thiola EC, Cholbam, and Chenodal. The company also supports specialized care through disease-focused programs and physician engagement aimed at addressing conditions with limited treatment options. Travere Therapeutics Inc. serves patients, healthcare providers, and rare-disease communities across its core therapeutic areas, combining approved medicines with ongoing development work in nephrology and metabolic disease. Headquartered in San Diego, California, Travere Therapeutics Inc. plays a notable role in the rare-disease biopharmaceutical market through its focused product set and concentrated clinical expertise.
Website3611 Valley Centre Drive
San Diego, CA, 92130
United States
The latest articles about TVTX.
Summary of Nov 3's posts. Generated by AI.
Summary of Oct 15's posts. Generated by AI.
Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.
Summary of Apr 15's posts. Generated by AI.
Summary of Oct 15's posts. Generated by AI.
Investors talking about TVTX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.